PYFA Holds Emergency Hypertension Management Symposium to Commemorate World Stroke Day

Semarang, December 8, 2025 – PYFA, through its subsidiary PT Ethica Industri Farmasi, has once again demonstrated its commitment to supporting the advancement of Indonesian healthcare. Coinciding with the commemoration of World Stroke Day, PYFA Group collaborated with the Indonesian Neurological Association (PERDOSNI) to participate in a scientific meeting attended by 300 neurologists in Semarang.

This event served as a scientific discussion forum for healthcare professionals through a special symposium titled Management of Hypertensive Emergencies during Stroke. This step was taken in response to the urgency of handling hypertensive emergencies—a condition where blood pressure surges above 180/120 mmHg, posing a fatal risk of causing a stroke. Data released by the Ministry of Health in Mediakom (153rd edition) shows that stroke is the number one cause of death, with an estimated 131.8 deaths per 100,000 residents.

Through this scientific forum, PYFA Group officially introduced Labetalol, a therapeutic innovation long-awaited by medical practitioners in Indonesia. Although Labetalol has long been recognized globally as a first-line choice for managing hypertensive emergencies abroad, the availability of this active substance in Indonesia has been very limited.

PYFA Group’s presence in this symposium aimed to provide in-depth education to neurologists that Labetalol is now officially available in Indonesia. This product offers a rapid and safe mechanism for lowering blood pressure, a crucial factor during the “golden period” of stroke patient management to minimize further neurological damage. Complementing the comprehensive stroke management solution, PYFA Group also introduced Cytoflavin, intended for patients who have already suffered a stroke. As a neuroprotector, Cytoflavin works to protect brain cells from further damage by promoting cellular respiration and metabolism, ensuring brain cells retain sufficient energy to support the recovery process.

“Our focus in this agenda is to target healthcare professionals through a scientific approach. We want to ensure that doctors in Indonesia have access to therapeutic options of the same quality as global standards. With the presence of Labetalol and Cytoflavin, we hope the management of hypertensive emergency cases and stroke cases in Indonesia can become more effective and save more lives,” said Antes Eko Prasetio, Chief Commercial Officer of PT Pyridam Farma Tbk (PYFA Group).

PYFA Group’s participation in the World Stroke Day commemoration in Semarang further affirms the company’s position both as a provider of medicines and as a strategic partner for medical personnel in improving national healthcare standards through the provision of innovative and proven pharmaceutical products.